Autism Clinical Trials: Biological and Medical Issues in Patient Selection and Treatment Response

George M. Anderson, Andrew W. Zimmerman, Natacha Akshoomoff, Diane C. Chugani

Research output: Contribution to journalArticle

Abstract

Biomedical measures are critical in the initial patient-screening and -selection phases of a clinical trial in autism and related disorders. These measures can also play an important role in the assessment and characterization of response and can provide an opportunity to study underlying etiologic and pathophysiologic processes. Thus, biomedical measures, including clinical laboratory analyses, metabolic screening, and chromosomal analysis, are used to screen for potential safety-related problems, to decrease biological and genetic heterogeneity, and to define subgroups. Neurobiological measures can be examined as possible predictors, modifiers or surrogates of therapeutic response, and adverse effects. Neurobiological research measures can also be used to study mechanisms and extent of drug action and to perform baseline and longitudinal investigations of possible pathophysiologic alterations. The potential utility and desirability of specific measures are considered and the general approach to choosing measures for incorporation is discussed.

Original languageEnglish (US)
Pages (from-to)57-64
Number of pages8
JournalCNS Spectrums
Volume9
Issue number1
StatePublished - Jan 2004

Fingerprint

Genetic Heterogeneity
Autistic Disorder
Patient Selection
Clinical Trials
Safety
Research
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology

Cite this

Anderson, G. M., Zimmerman, A. W., Akshoomoff, N., & Chugani, D. C. (2004). Autism Clinical Trials: Biological and Medical Issues in Patient Selection and Treatment Response. CNS Spectrums, 9(1), 57-64.

Autism Clinical Trials : Biological and Medical Issues in Patient Selection and Treatment Response. / Anderson, George M.; Zimmerman, Andrew W.; Akshoomoff, Natacha; Chugani, Diane C.

In: CNS Spectrums, Vol. 9, No. 1, 01.2004, p. 57-64.

Research output: Contribution to journalArticle

Anderson, GM, Zimmerman, AW, Akshoomoff, N & Chugani, DC 2004, 'Autism Clinical Trials: Biological and Medical Issues in Patient Selection and Treatment Response', CNS Spectrums, vol. 9, no. 1, pp. 57-64.
Anderson GM, Zimmerman AW, Akshoomoff N, Chugani DC. Autism Clinical Trials: Biological and Medical Issues in Patient Selection and Treatment Response. CNS Spectrums. 2004 Jan;9(1):57-64.
Anderson, George M. ; Zimmerman, Andrew W. ; Akshoomoff, Natacha ; Chugani, Diane C. / Autism Clinical Trials : Biological and Medical Issues in Patient Selection and Treatment Response. In: CNS Spectrums. 2004 ; Vol. 9, No. 1. pp. 57-64.
@article{8971814c71314fd7bb4f297359497c0c,
title = "Autism Clinical Trials: Biological and Medical Issues in Patient Selection and Treatment Response",
abstract = "Biomedical measures are critical in the initial patient-screening and -selection phases of a clinical trial in autism and related disorders. These measures can also play an important role in the assessment and characterization of response and can provide an opportunity to study underlying etiologic and pathophysiologic processes. Thus, biomedical measures, including clinical laboratory analyses, metabolic screening, and chromosomal analysis, are used to screen for potential safety-related problems, to decrease biological and genetic heterogeneity, and to define subgroups. Neurobiological measures can be examined as possible predictors, modifiers or surrogates of therapeutic response, and adverse effects. Neurobiological research measures can also be used to study mechanisms and extent of drug action and to perform baseline and longitudinal investigations of possible pathophysiologic alterations. The potential utility and desirability of specific measures are considered and the general approach to choosing measures for incorporation is discussed.",
author = "Anderson, {George M.} and Zimmerman, {Andrew W.} and Natacha Akshoomoff and Chugani, {Diane C.}",
year = "2004",
month = "1",
language = "English (US)",
volume = "9",
pages = "57--64",
journal = "CNS Spectrums",
issn = "1092-8529",
publisher = "MBL Communications",
number = "1",

}

TY - JOUR

T1 - Autism Clinical Trials

T2 - Biological and Medical Issues in Patient Selection and Treatment Response

AU - Anderson, George M.

AU - Zimmerman, Andrew W.

AU - Akshoomoff, Natacha

AU - Chugani, Diane C.

PY - 2004/1

Y1 - 2004/1

N2 - Biomedical measures are critical in the initial patient-screening and -selection phases of a clinical trial in autism and related disorders. These measures can also play an important role in the assessment and characterization of response and can provide an opportunity to study underlying etiologic and pathophysiologic processes. Thus, biomedical measures, including clinical laboratory analyses, metabolic screening, and chromosomal analysis, are used to screen for potential safety-related problems, to decrease biological and genetic heterogeneity, and to define subgroups. Neurobiological measures can be examined as possible predictors, modifiers or surrogates of therapeutic response, and adverse effects. Neurobiological research measures can also be used to study mechanisms and extent of drug action and to perform baseline and longitudinal investigations of possible pathophysiologic alterations. The potential utility and desirability of specific measures are considered and the general approach to choosing measures for incorporation is discussed.

AB - Biomedical measures are critical in the initial patient-screening and -selection phases of a clinical trial in autism and related disorders. These measures can also play an important role in the assessment and characterization of response and can provide an opportunity to study underlying etiologic and pathophysiologic processes. Thus, biomedical measures, including clinical laboratory analyses, metabolic screening, and chromosomal analysis, are used to screen for potential safety-related problems, to decrease biological and genetic heterogeneity, and to define subgroups. Neurobiological measures can be examined as possible predictors, modifiers or surrogates of therapeutic response, and adverse effects. Neurobiological research measures can also be used to study mechanisms and extent of drug action and to perform baseline and longitudinal investigations of possible pathophysiologic alterations. The potential utility and desirability of specific measures are considered and the general approach to choosing measures for incorporation is discussed.

UR - http://www.scopus.com/inward/record.url?scp=1842453637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842453637&partnerID=8YFLogxK

M3 - Article

C2 - 14999176

AN - SCOPUS:1842453637

VL - 9

SP - 57

EP - 64

JO - CNS Spectrums

JF - CNS Spectrums

SN - 1092-8529

IS - 1

ER -